Barclays PLC Buys 16,382 Shares of Seer, Inc. (NASDAQ:SEER)

Barclays PLC increased its holdings in shares of Seer, Inc. (NASDAQ:SEER) by 34.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,426 shares of the company’s stock after purchasing an additional 16,382 shares during the quarter. Barclays PLC owned 0.11% of Seer worth $127,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Seer during the second quarter valued at about $148,000. GSA Capital Partners LLP grew its stake in shares of Seer by 194.9% in the 3rd quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock worth $252,000 after buying an additional 84,515 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Seer in the 2nd quarter valued at approximately $133,000. XTX Topco Ltd purchased a new stake in shares of Seer in the third quarter valued at $123,000. Finally, Quadrature Capital Ltd grew its stake in shares of Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after buying an additional 42,875 shares during the last quarter. Institutional investors own 75.20% of the company’s stock.

Seer Trading Up 1.7 %

NASDAQ SEER opened at $2.41 on Friday. The stock has a market cap of $142.12 million, a PE ratio of -1.85 and a beta of 1.57. The company’s 50-day moving average price is $2.38 and its 200-day moving average price is $2.03. Seer, Inc. has a 12 month low of $1.51 and a 12 month high of $2.63.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.